The impact of statin treatment on presentation mode and early outcomes in acute coronary syndromes

Cardiology

Volumn 109, Issue 3, 2008, Pages 156-162

  Cuculi, F ^a   Radovanovic, D ^a   Eberli, F R ^a   Stauffer, J C ^a   Bertel, O ^a   Erne, P ^a  

^a Kantonsspital Luzern ^*  (Switzerland)

Author keywords

Acute coronary syndromes; AMIS project; Presentation mode; Statin therapy

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; SWITZERLAND; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SWITZERLAND; TREATMENT OUTCOME;

EID: 38949200388     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106676     Document Type: Article

References (23)

1. Hoeg JM, Brewer HB Jr: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987;258:3532-3536.
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
3. Anand SS: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ 2003;326:1407-1408. Vasc Med 2003;8:289-290.
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
5. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A: Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-1436.
6. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC: Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005;165:725-730.
7. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Karas RH: Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003;139:670-682.
8. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
9. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-1566.
10. Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109:II18-II26.
11. Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Froland SS, Semb AG, Aukrust P, Damas JK: Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMGCoA reductase inhibitors. Circulation 2004;109:1966-1972.
12. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718.
13. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction I: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
14. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; A to Z Investigators: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316.
15. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es G-A, Kayikcioglu M, Arntz H-R, den Hartog FR, Veeger NJGM, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ: Effects of early treatment with statins on shortterm clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006;295:2046-2056.
16. Hulten E, Jackson JL, Douglas K, George S, Villines TC: The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:1814-1821.
17. Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, Hlatky MA: Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med 2006;144:229-238.
18. Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, Mehta RH, Brieger D: Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004;140:857-866.
19. Erne P, Radovanovic D, Urban P, Stauffer JC, Bertel O, Gutzwiller F: Early drug therapy and in-hospital mortality following acute myocardial infarction. Heart Drug 2003;3:134-140.
20. Fassa AA, Urban P, Radovanovic D, Duvoisin N, Gaspoz JM, Stauffer JC, Erne P: Trends in reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a nationwide registry. Heart 2005;91:882-888.
21. Radovanovic D, Erne P, Schilling J, Noseda G, Gutzwiller F: Association of dyslipidemia and concomitant risk factors with in-hospital mortality in acute coronary syndrome in Switzerland. Heart Drug 2005;5:131-139.
22. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-1452.
23. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, Inoue K, Fujii K: Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006;27:534-539.